Prostate disorder
Therapeutic area
Reproductive Health
Rare disease
No
- Definition
- A disease involving the prostate gland.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Prostate disorder
- Therapeutic area
- Reproductive Health
- prostate disorder
- disease of prostate gland
- disease or disorder of prostate gland
- disorder of prostate gland
- prostate disease
- Prostate Disorders
- prostate gland disease
- prostate gland disease or disorder
- All therapeutic areas
- Reproductive Health
Sources for recorded values
- Severity
- Mild
- MONDO ID
- MONDO:0003105
- Parent condition
- MONDO:0003150
Related records
Broader conditions (5)
- Disease
- Disease by body system or component
- Human disease
- Male reproductive system disorder
- Reproductive system disorder
Narrower conditions (64)
- Acinar prostate adenocarcinoma, foamy gland variant
- Acinar prostate adenocarcinoma, signet ring variant
- Acinar prostate mucinous adenocarcinoma
- Acute gonococcal prostatitis
- Adenosquamous prostate carcinoma
- Benign neoplasm of prostate
- Benign prostate phyllodes tumor
- Benign prostatic hyperplasia
- Castration-resistant prostate carcinoma
- Chronic prostatitis
- Familial prostate carcinoma
- Fibroma of prostate
- Gonococcal prostatitis
- Grade III prostatic intraepithelial neoplasia
- Granulomatous prostatitis
- Hormone-resistant prostate carcinoma
- Lymphoepithelioma-like acinar prostate adenocarcinoma
- Malignant prostate phyllodes tumor
- Metastatic prostate carcinoma
- Primary prostate urothelial carcinoma
Trials (85)
- 177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
- 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
- 4-aminopyridine Treatment for Nerve Injury From Radical Retro-Pubic Prostatectomy
- 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
- 68Ga-HTK03149 for Use as a Diagnostic Radiopharmaceutical
- 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
- A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
- A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study
- A Phase 3 Study of [177Lu]Ludotadipep for Metastatic Castration-Resistant Prostate Cancer
- A Prospective Trial of Povidone-iodine Suppository Before Transrectal Ultrasound Guided Prostate Biopsy
- A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
- A Study of FT-7051 in Men With MCRPC
- A Study of Ixabepilone Before Surgery for High-Risk Localized Prostate Cancer
- A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8)
- A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002)
- Alfuzosin XL Lower Urinary Tract Symptoms Efficacy and Sexuality Study
- Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
- Antibiotic Prophylaxis for Transrectal Prostate Biopsy-Ciprofloxacin vs. Trimethoprim/Sulfamethoxazole
- Benign Prostatic Hyperplasia in Taiwan
- Biobank for African American Prostate Cancer Research in Florida
Approved drugs (1)
- Plazomicin
Drugs in development (6)
- Dalfampridine Phase 2
- Fiduxosin hydrochloride Phase 2
- Finrozole Phase 2
- ILX23-7553 Phase 1
- Ozarelix Phase 2
- Turosteride Phase 2
Other linked drugs (2)
- Alfuzosin
- Gallium GA 68 gozetotide